JP2021519061A5 - - Google Patents

Info

Publication number
JP2021519061A5
JP2021519061A5 JP2020551264A JP2020551264A JP2021519061A5 JP 2021519061 A5 JP2021519061 A5 JP 2021519061A5 JP 2020551264 A JP2020551264 A JP 2020551264A JP 2020551264 A JP2020551264 A JP 2020551264A JP 2021519061 A5 JP2021519061 A5 JP 2021519061A5
Authority
JP
Japan
Prior art keywords
cells
induced
cell
genome
construct according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020551264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519061A (ja
JP7575271B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2018/067289 external-priority patent/WO2019126748A1/en
Application filed filed Critical
Priority claimed from PCT/US2019/024686 external-priority patent/WO2019191495A1/en
Publication of JP2021519061A publication Critical patent/JP2021519061A/ja
Publication of JP2021519061A5 publication Critical patent/JP2021519061A5/ja
Priority to JP2024181460A priority Critical patent/JP2025013853A/ja
Application granted granted Critical
Publication of JP7575271B2 publication Critical patent/JP7575271B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020551264A 2018-03-29 2019-03-28 操作された免疫エフェクター細胞およびその使用 Active JP7575271B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024181460A JP2025013853A (ja) 2018-03-29 2024-10-17 操作された免疫エフェクター細胞およびその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862649781P 2018-03-29 2018-03-29
US62/649,781 2018-03-29
US201862774052P 2018-11-30 2018-11-30
US62/774,052 2018-11-30
PCT/US2018/067289 WO2019126748A1 (en) 2017-12-22 2018-12-21 Enhanced immune effector cells and use thereof
USPCT/US2018/067289 2018-12-21
PCT/US2019/024686 WO2019191495A1 (en) 2018-03-29 2019-03-28 Engineered immune effector cells and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024181460A Division JP2025013853A (ja) 2018-03-29 2024-10-17 操作された免疫エフェクター細胞およびその使用

Publications (3)

Publication Number Publication Date
JP2021519061A JP2021519061A (ja) 2021-08-10
JP2021519061A5 true JP2021519061A5 (https=) 2022-04-04
JP7575271B2 JP7575271B2 (ja) 2024-10-29

Family

ID=68060556

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020551264A Active JP7575271B2 (ja) 2018-03-29 2019-03-28 操作された免疫エフェクター細胞およびその使用
JP2024181460A Pending JP2025013853A (ja) 2018-03-29 2024-10-17 操作された免疫エフェクター細胞およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024181460A Pending JP2025013853A (ja) 2018-03-29 2024-10-17 操作された免疫エフェクター細胞およびその使用

Country Status (12)

Country Link
US (1) US20210024959A1 (https=)
EP (1) EP3775228B1 (https=)
JP (2) JP7575271B2 (https=)
KR (2) KR102817092B1 (https=)
CN (1) CN111954715A (https=)
AU (2) AU2019243315A1 (https=)
BR (1) BR112020019205A2 (https=)
CA (1) CA3093020A1 (https=)
IL (1) IL277611A (https=)
MX (1) MX2020009896A (https=)
SG (1) SG11202008977UA (https=)
WO (1) WO2019191495A1 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021178933A2 (en) 2020-03-06 2021-09-10 Metagenomi Ip Technologies, Llc Class ii, type v crispr systems
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
IL316257A (en) 2017-12-22 2024-12-01 Fate Therapeutics Inc Enhanced immune effector cells and use thereof
CN110628821B (zh) * 2018-06-25 2022-02-18 首都医科大学宣武医院 一种细胞模型及其制备方法、应用
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
JP7595583B2 (ja) * 2019-04-30 2024-12-06 アタラ バイオセラピューティクス，インコーポレーテッド 抗原特異的ｃｄ１９標的化ｃａｒ－ｔ細胞
JP7728747B2 (ja) * 2019-08-23 2025-08-25 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ２４発現細胞およびそれらの用途
EP4041759A4 (en) * 2019-10-07 2023-12-20 Fate Therapeutics, Inc. IMPROVED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL CULTURE AND USE THEREOF
EP4045539A4 (en) * 2019-10-17 2024-03-13 Fate Therapeutics, Inc. Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
US20230149511A1 (en) * 2020-04-09 2023-05-18 Wallkill BioPharma, Inc. Treating autoimmune diseases with genetically modified cells
JP2023524976A (ja) * 2020-05-04 2023-06-14 エディタス・メディシン、インコーポレイテッド 必須遺伝子ノックインによる選択
BR112022025806A2 (pt) * 2020-06-19 2023-03-07 Fate Therapeutics Inc Combinação de tipos de células efetoras derivadas de ipsc para uso em imunoterapia
JP2023541457A (ja) * 2020-09-14 2023-10-02 ブイオーアール バイオファーマ インコーポレーテッド Ｃｄ３８修飾のための化合物および方法
CN114457025A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达btla阻断物的多能干细胞或其衍生物及应用
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
KR20230118887A (ko) 2020-12-03 2023-08-14 센츄리 쎄라퓨틱스 인코포레이티드 유전자 조작 세포 및 이의 용도
CN114107211B (zh) * 2020-12-04 2025-09-30 未来智人再生医学研究院(广州)有限公司 一种多能干细胞及其衍生物
CN114645018A (zh) * 2020-12-18 2022-06-21 未来智人再生医学研究院(广州)有限公司 一种表达cd38靶向抑制因子的多能干细胞及其衍生物与应用
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
CN114657137A (zh) * 2020-12-22 2022-06-24 未来智人再生医学研究院(广州)有限公司 一种表达靶向BTLA的shRNA和/或shRNA-miR的多能干细胞或其衍生物
CN114657133A (zh) * 2020-12-22 2022-06-24 未来智人再生医学研究院(广州)有限公司 一种表达靶向IL-4 Rα的shRNA和/或shRNA-miR的多能干细胞
EP4305053A1 (en) * 2021-03-11 2024-01-17 Kite Pharma, Inc. Improving immune cell function
AU2022271241A1 (en) * 2021-05-04 2023-11-23 Shoreline Biosciences, Inc. Engineered cells for therapy
BR112023024983A2 (pt) * 2021-06-02 2024-04-30 Metagenomi Inc Sistemas crispr classe ii, tipo v
US20240316102A1 (en) 2021-07-01 2024-09-26 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
CN113278652B (zh) * 2021-07-20 2021-10-01 卡瑞济(北京)生命科技有限公司 增加Survivin表达的CAR-T细胞并联合IL-15在制备抗肿瘤药物中的应用
CN115989244A (zh) * 2021-08-06 2023-04-18 上海驯鹿生物技术有限公司 Cd5和cd7双靶点的全人源嵌合抗原受体(car)及其应用
CN117835993A (zh) * 2021-08-18 2024-04-05 菲特治疗公司 作为单一疗法以及与抗体组合的现成的iPSC衍生的CAR-NK细胞
CN116103239A (zh) * 2021-11-11 2023-05-12 南京北恒生物科技有限公司 工程化免疫细胞及其用途
CN118284686A (zh) * 2021-11-24 2024-07-02 杭州启函生物科技有限公司 用于基于细胞的免疫疗法的系统和方法
JP2025501617A (ja) * 2021-12-24 2025-01-22 ヘマセル バイオテクノロジー インコーポレイテッド 相同組換え及びインテグラーゼ媒介性組換えによりヒト人工多能性幹細胞を製造する方法
CN116804185A (zh) * 2022-03-25 2023-09-26 士泽生物医药（苏州）有限公司 一种通用型细胞及其制备方法
US20250228943A1 (en) 2022-04-08 2025-07-17 Fate Therapeutics, Inc. Cells having solid tumor targeting backbone and use thereof
US20250222029A1 (en) 2022-04-08 2025-07-10 Fate Therapeutics, Inc. Chimeric antigen receptor for tumor targeting
CN116948012B (zh) * 2022-04-13 2024-07-26 星奕昂(上海)生物科技有限公司 增强细胞功能的cd16抗剪切突变体
AU2023276763A1 (en) 2022-05-25 2024-12-12 Metagenomi Therapeutics, Inc. Supplementation of liver enzyme expression
CN114774469B (zh) * 2022-06-22 2022-11-08 南京艾尔普再生医学科技有限公司 一种adcc功能增强的nk细胞的制作方法、nk细胞及其组合物
JP2025525439A (ja) 2022-06-30 2025-08-05 インダプタ セラピューティクス インコーポレイテッド 操作されたナチュラルキラー（ｎｋ）細胞と抗体療法との組み合わせおよび関連する方法
WO2024050138A2 (en) * 2022-09-02 2024-03-07 Myeloid Therapeutics, Inc. Compositions for cell-specific expression and uses thereof
IL319793A (en) * 2022-09-22 2025-05-01 Myeloid Therapeutics Inc Engineered chimeric fusion protein compositions and methods for using them
WO2024102704A2 (en) * 2022-11-07 2024-05-16 Fate Therapeutics, Inc. Ipsc-derived nk cell targeting mica/b for solid tumor treatment
WO2024183750A1 (en) * 2023-03-07 2024-09-12 Qihan Hong Kong Limited A novel immune cell and use thereof for treating diseases
WO2024211852A1 (en) * 2023-04-07 2024-10-10 Fate Therapeutics, Inc. Ipsc-derived nk cell for lymphoma treatment
AU2024269870A1 (en) * 2023-05-05 2025-11-20 Board Of Regents, The University Of Texas System Multi-receptor natural killer cells
CN116286905B (zh) * 2023-05-11 2023-08-15 内蒙古大学 牛源化CRISPR/boCas9基因编辑系统、方法及应用
CN119371550A (zh) * 2023-08-10 2025-01-28 深圳市三启生物技术有限公司 含有gprc5d抗体的嵌合抗原受体及其应用
WO2025102504A1 (zh) * 2023-11-15 2025-05-22 复旦大学 基于i型内含子的环状rna制备方法及其应用
WO2025240349A2 (en) * 2024-05-15 2025-11-20 Be Biopharma, Inc. Allogeneic cell compositions and methods thereof
WO2025257119A1 (en) * 2024-06-10 2025-12-18 Repairon Immuno Gmbh Method of producing a modified immune cell from a pluripotent stem cell (psc)
CN119264271B (zh) * 2024-10-08 2025-05-09 北京市神经外科研究所 一种nk细胞特异性的嵌合抗原受体及其应用
CN121159717B (zh) * 2025-09-11 2026-04-21 中邦干细胞科技有限公司 一种嵌合蛋白、工程化nk细胞及其制备方法和用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5766944A (en) * 1996-12-31 1998-06-16 Ruiz; Margaret Eileen T cell differentiation of CD34+ stem cells in cultured thymic epithelial fragments
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
JP2005500061A (ja) 2001-08-20 2005-01-06 ザ スクリップス リサーチ インスティテュート Ｃｎｎについての亜鉛フィンガー結合ドメイン
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
WO2011072246A2 (en) 2009-12-10 2011-06-16 Regents Of The University Of Minnesota Tal effector-mediated dna modification
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
CA2861491C (en) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
BR112014029417B1 (pt) 2012-05-25 2023-03-07 Cellectis Método ex vivo para a preparação de células t para imunoterapia
DK2956175T3 (da) 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
KR102375998B1 (ko) 2014-02-14 2022-03-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 항원 수용체 및 제조방법
WO2015121454A1 (en) * 2014-02-14 2015-08-20 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
US10934346B2 (en) 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
PT3122769T (pt) * 2014-03-28 2023-04-24 Univ Minnesota Polipéptidos, células e métodos que envolvem cd16 manipulado
KR20170032406A (ko) * 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 조작된 세포
AU2015312117A1 (en) 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
HK1255161A1 (zh) * 2015-07-15 2019-08-09 Juno Therapeutics, Inc. 用於过继性细胞治疗的工程细胞
WO2017025323A1 (en) * 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
KR20250141836A (ko) * 2015-11-04 2025-09-29 페이트 세러퓨틱스, 인코포레이티드 만능 세포의 유전자 조작
US20170166877A1 (en) 2015-12-14 2017-06-15 Bellicum Pharmaceuticals, Inc. Dual controls for therapeutic cell activation or elimination
JP7653759B2 (ja) * 2016-01-20 2025-03-31 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
IL316257A (en) * 2017-12-22 2024-12-01 Fate Therapeutics Inc Enhanced immune effector cells and use thereof

Similar Documents

Publication Publication Date Title
JP2021519061A5 (https=)
JP2022550899A5 (https=)
JP2022548943A5 (https=)
JP2022527405A5 (https=)
JP2022541441A5 (https=)
JP2021505131A5 (https=)
JP2022510207A5 (https=)
JP2023548467A5 (https=)
JP2023505206A5 (https=)
JP2023549098A5 (https=)
JP2023530704A5 (https=)
Lipowska-Bhalla et al. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges
JP2023548829A5 (https=)
JP7623020B2 (ja) 同種異系移植のための操作された免疫細胞
EP4166655A1 (en) Engineered immune cell and use thereof
US10925943B2 (en) Marker-suicide gene useful in adoptive cell therapy
JP2024518011A5 (https=)
JP2023545992A5 (https=)
CN112029001A (zh) 靶向nk激活性受体的嵌合抗原受体
IL314563A (en) Non-HLA-restricted T-cell receptors and their uses
JP2022552314A5 (https=)
JP2022531222A5 (https=)
JP7636650B2 (ja) 二量体形成剤調節性免疫受容体複合体
JP2018522567A (ja) 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞
JP2017512054A (ja) 三官能性ｔ細胞−抗原カプラ及び方法並びにこれらの使用